Corticosteroid-related central nervous system side effects. 2013

Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
Department of Science of Health, School of Medicine, University of Catanzaro and Pharmacovigilance's Centre Calabria Region, University Hospital Mater Domini, Italy.

Corticosteroids have been used since the 50s as anti-inflammatory and immunosuppressive drugs for the treatment of several pathologies such as asthma, allergy, rheumatoid arthritis, and dermatological disorders. Corticosteroids have three principal mechanisms of action: 1) inhibit the synthesis of inflammatory proteins blocking NF-kB, 2) induce the expression of anti-inflammatory proteins by IkB and MAPK phosphatase I, and 3) inhibit 5-lipoxygenase and cyclooxygenase-2. The efficacy of glucocorticoids in alleviating inflammatory disorders results from the pleiotropic effects of the glucocorticoid receptors on multiple signaling pathways. However, they have adverse effects: Growth retardation in children, immunosuppression, hypertension, hyperglycemia, inhibition of wound repair, osteoporosis, metabolic disturbances, glaucoma, and cataracts. Less is known about psychiatric or side effects on central nervous system, as catatonia, decreased concentration, agitation, insomnia, and abnormal behaviors, which are also often underestimated in clinical practice. The aim of this review is to highlight the correlation between the administration of corticosteroids and CNS adverse effects, giving a useful guide for prescribers including a more careful assessment of risk factors and encourage the use of safer doses of this class of drugs.

UI MeSH Term Description Entries

Related Publications

Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
April 1987, Deutsche medizinische Wochenschrift (1946),
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
March 1990, The New England journal of medicine,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
November 1982, Journal of the Medical Association of Georgia,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
June 1981, General hospital psychiatry,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
August 1988, International journal of clinical pharmacology, therapy, and toxicology,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
April 1988, Archives of internal medicine,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
January 1990, Pharmacology & therapeutics,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
June 1986, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
April 1990, The American journal of the medical sciences,
Miriam Ciriaco, and Pasquale Ventrice, and Gaetano Russo, and Maria Scicchitano, and Giovanni Mazzitello, and Francesca Scicchitano, and Emilio Russo
January 2000, Clinical neuropharmacology,
Copied contents to your clipboard!